Ovarian Cancer – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Ovarian Cancer (OC) is the eighth most common cancer in women. Worldwide incidence cases range between 299,414 to 312,500 new cases in 2020. OC is amongst the leading causes of cancer-related death in women, particularly in the 40–79 age group. Survival rates vary significantly depending on the disease stage at diagnosis. Around 70 to 80% of patients are diagnosed in their advanced stages of the disease with a 5-year survival of 29 to 30%; ninety percent of patients with early-stage disease are alive at ten years compared with only around 15% with advanced disease, despite optimal treatment. A woman’s lifetime risk of developing OC is 1 in 75, and her chance of dying of the disease is 1 in 100. First-degree relatives of probands have a 3- to 7-fold increased risk if multiple relatives are affected early. Rare high penetrant mutations in the BRCA1 and BRCA2 genes increase lifetime risk substantially and account for most hereditary cases and 10%–15% of all topics.

 

The three major types of ovarian cancer are epithelial, accounting for 90% of cases, germ cell (3%), and sex cord-stromal (2%). Epithelial cancers are further subdivided into severe (52%), endometrioid (10%), mucinous (6%), and clear cell (6%) tumors.

 

The competitive landscape of Ovarian Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Ovarian Cancer across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Ovarian Cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Ovarian Cancer – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          CYTALUX™ (pafolacianine)       On Target Laboratories, Inc.            Phase 2/3

2          XMT-1536 (Upifitamab Rilsodotin)          Mersana Therapeutics            Phase 1/2

3          Doxorubicin Hydrochloride Liposome Injection    Ayana Pharma Ltd.,     Phase 1/2

4          Karenitecin        BioNumerik Pharmaceuticals, Inc.          Phase 3

5          Magrolimab and Avelumab         Gilead Sciences            Phase 1

6          2X-121 Allarity Therapeutics      Phase 2

7          chiauranib         Chipscreen Biosciences, Ltd.     Phase 2

8          Batiraxcept       Aravive, Inc.      Phase 3

9          OMP-54F28, Paclitaxel and Carboplatin  OncoMed Pharmaceuticals, Inc.       Phase 1

10        IMAB027          Ganymed Pharmaceuticals GmbH         Phase 1

Continued

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more